By RHONDA
L. RUNDLE and ANNA WILDE MATHEWS
Staff
Reporters of THE WALL STREET JOURNAL
The disclosure of pumped-up Medicare revenue at
Tenet Healthcare Corp., the nation's second-largest publicly traded
hospital company, has exposed a flaw in the Medicare system: By
raising rates sharply, Tenet hospitals triggered an obscure mechanism
that automatically boosted their payments.
At issue is Tenet's outsize revenue from
supplemental fees for the most expensive patients, called "outliers"
in Medicare terminology. Those fees, according to Medicare data, are
making up nearly a quarter of the company's projected revenue this
fiscal year from the federal medical-insurance system for senior
citizens -- and brought in $412 million more in 2002 than just two
years earlier. Medicare's top administrator said in an interview this
weekend that the mechanism "invited gaming" and has to be changed.
Tenet is in mounting crisis amid a federal audit
into the payments. At the same time, two heart doctors that work in a
Tenet hospital -- two of the top Medicare billers in their specialties
in Northern California -- have drawn a fact-finding raid by FBI agents
looking into whether they performed unnecessary surgeries and other
procedures. Tenet's stock price has dropped by 72% since Oct. 28 and
Standard & Poor's and Fitch have cut its debt rating.
Chief Executive Jeffrey C. Barbakow last week
responded by cleaning house, bringing in a new second in command and
crowding out chief operating officer Thomas B. Mackey, who developed
the company's aggressive pricing strategy, and chief financial officer
David L. Dennis, Mr. Barbakow's longtime friend.
|
|
FULL COVERAGE
Listen to a Tenet conference call1 on Medicare
payments.
For more health coverage, visit the Online Journal's
Health Industry Edition at wsj.com/health2 and
receive daily health e-mails3.
|
|
|
|
|
|
The company is not accused of any wrongdoing.
Tenet officials say they didn't encourage doctors to perform expensive
operations, or change the company's pricing structure to deliberately
gouge Medicare. They say the increased payments were a side effect of
the company's growing size and clout in California and other markets
that allowed it to raise rates it charged health insurers.
Tom Scully, administrator of the Centers for
Medicare & Medicaid Services in Washington, said the Medicare
mechanism that Tenet profited from had to be fixed. "I can guarantee
you in the next couple of weeks, we'll have a new proposal" he said.
"It's now No. 1 on my list of things to do." Mr. Scully declined to
comment specifically on the Tenet case.
But auditors will look at whether Tenet went too
far. Among the nation's big hospital chains, Tenet gets by far the
highest percentage of its Medicare income from supplemental payments
for the most expensive patients, called "outliers." HCA-The Healthcare
Co., the largest hospital company, is projected to get only 5% of its
Medicare revenue from outlier payments in fiscal 2003, compared with
23.5% for Tenet, according to Medicare data.
Tenet's aggressive strategy helped transform the
company into a Wall Street darling in the last three years, as it
posted a string of stellar earnings reports. Its stock price soared,
allowing executives at the Santa Barbara-based firm to reap tens of
millions of dollars selling shares and exercising options. It
represented an impressive turnaround for Mr. Barbakow, who was brought
in to clean up Tenet nine years ago after its predecessor company,
National Medical Enterprises Inc., was nearly destroyed by
criminal
fraud charges against its psychiatric hospitals, which it later sold.
One of those profiting from the soaring stock was
Mr. Mackey, the chief operating officer. On Oct. 4, Mr. Mackey sold
277,500 shares of Tenet stock at $51.50 a share, garnering $14.3
million. That was a day after a 52-week high and a few weeks before an
Oct. 28 analyst's report about Tenet's reliance on outlier payments
sent the stock falling. The company says Mr. Mackey exercised option
grants. Mr. Mackey didn't respond to several messages left for him.
Mr. Barbakow sparred with investors in a
conference call last week that stretched nearly three hours.He said in
an interview this weekend that he hasn't "found any evidence as of
this point" that Tenet was doing anything wrong. But he says the
pricing strategy's effect on Medicare payments "puts the company in a
position I don't feel comfortable with."
The market's reaction to the events has been swift
and severe. Instead of reassuring investors, Mr. Barbakow's actions --
and statements that he wasn't aware of the details of the pricing
strategy -- have made them worried that Tenet's situation could
turnworse. U.S. Rep. Pete Stark, a California Democrat, compares
Tenet's actions with those of HCA, which two years ago paid a record
$840 million in criminal fines, civil penalties and damages to end a
government probe of its Medicare billing practices.
The company's defenders argue that the Medicare
system itself is largely to blame for a reimbursement formula that
resulted in outsize payments to Tenet. Health-industry executives
frequently criticize the system for being so convoluted and full of
gray areas that it invites abuse. The Medicare handbook for hospitals
and physicians is more than 100,000 pages long and "represents more
than 35 years of regulations, changes, adjustments and readjustments,"
said Ken Weakley, an analyst at UBS Warburg., author of the Oct. 28
report on Tenet's outlier payments.
A question for auditors is whether the enlarged
payments to Tenet hospitals were proper or whether the company
deliberately set up its pricing structure to manipulate the
reimbursement system for greater gains.
The trail begins in 1999, after Tenet consolidated
two big acquisitions that brought it a slew of new hospitals in
California, its largest market and home state. The competitive
landscape there was shifting. A consumer revolt against managed care
had weakened the state's powerful health-maintenance organizations,
giving hospitals more clout in negotiating deals to treat the HMOs'
patients.
Mr. Mackey, who had overseen the Western region,
took over the nuts and bolts of Tenet's hospital operations
nationwide. Mr. Mackey, a National Medical veteran who had joined the
company in 1985, faced a grim situation. A cutback in hospital
Medicare payments had flattened Tenet's revenue growth, depressed its
stock and forced a wrenching 30% cut in corporate overhead spending.
Mr. Mackey developed a policy to raise so-called
chargemaster prices, a kind of health-care equivalent of the sticker
price at car lots. Insurers and the government don't actually pay
chargemaster rates. But they are used in complex pricing formulas that
determine how much Medicare pays in supplemental fees for outliers,
expensive cases that exceed normal fixed rates.
As Tenet raised its prices aggressively, the ratio
used to calculate Medicare payments for such cases was thrown badly
out of whack. It triggered a decades-old mechanism that substitutes a
ratio of statewide average costs and charges. The mechanism was
designed to determine payments when data from individual hospitals
appeared wildly inaccurate.It boosted the payments to Tenet. In
essence, Tenet reaped rewards by triggering a hidden jackpot in the
Medicare system. None of HCA's hospitals are receiving any payments
from the substitute ratio, Mr. Weakley reported.
Tenet's price increases became more aggressive in
2000 after Mr. Dennis, a veteran investment banker, became Tenet's
chief financial officer. He stepped up pressure to keep Tenet's
revenue growing swiftly and instituted high performance targets at the
corporate level, people close to the situation say. That set up a race
between Mr. Mackey and Mr. Dennis to achieve ever-better financial
results, those people say. They add that tensions developed inside
Tenet's headquarters as some managers started to feel uncomfortable
with the hard-charging style of Mr. Barbakow's two top lieutenants.
Mr. Barbakow says, "I'm not arguing with that, but I didn't see that."
Mr. Dennis did not return calls for comment.
The impact of the stepped-up outlier payments on
Tenet was enormous. Those payments increased to $763 million in fiscal
2002, up from $351 million two years earlier. Almost two-thirds of the
2002 number -- $481 million -- came from Tenet hospitals that
benefited from the statewide average multiplier. That also represented
46 cents of the company's $2.17 per share earnings from operations.
Tenet believes that in the current fiscal year, it will collect even
more, $515 million, from these statewide average payments. That would
be 50 cents of the company's projected per-share earnings for 2003 of
$2.93, based on a 25% increase in adjusted earnings from 2002.
Mr. Barbakow says that he had never focused on the
financial impact of the outlier payments until sometime in the week of
Oct. 14 when Mr. Weakley, the UBS Warburg analyst, called to ask
questions of a Tenet investor-relations executive, who in turn talked
to Mr. Barbakow.
Two days after Mr. Weakley's report hit the
market, FBI agents raided Redding Medical Center and the offices of
two physicians, Dr. Chae Hyun Moon and Dr. Fidel Realyvasquez Jr. A
public affidavit prepared by an FBI agent and filed with the federal
court in Sacramento accused the two doctors of performing unnecessary
procedures including open-heart surgeries and angioplasties.
It is unclear what connection, if any, there could
be between the increased outlier payments and the FBI's interest in
the two doctors. One question it could raise is whether Tenet hospital
administrators may have pressured doctors in ways that encouraged them
to do unnecessary high-priced operations and procedures. "Flatly no,"
Mr. Barbakow says. "That hasn't been our strategy."
Neither the two doctors nor Tenet was charged with
any crime, but investors were spooked. Tenet has been stressing to
investors its success in attracting patients to its cardiology,
neurology and orthopedic departments, which are among the highest
billers in any hospital. Kevin Wenck, president of Polynous Capital
Management Inc., an investment firm in San Francisco that has a Tenet
stake, says people are wondering whether Tenet managers "prefer
revenue to quality of care."
According to the affidavit, Dr. Realyvasquez and
Dr. Moon were the Nos. 1 and 2 billers to the Medicare program in
their respective medical specialities in the Northern California
region. Redding also is one of Medicare's biggest beneficiaries of
outlier payments in the country. Upon news of the raid, Tenet's stock
fell another 26%
Dr. Moon, the head of Redding's cardiology
program, and Dr. Realyvasquez, a cardio-thoracic surgeon there, have
denied any wrongdoing. The two doctors and Redding Medical Center have
since been hit by at least four malpractice suits. Tenet announced
that it had hired an outside medical auditor to review the work of the
two Redding doctors. It also announced it will review treatments at
other company hospitals that generated high levels of outlier
payments.
Last week, Mr. Barbakow separately confronted Mr.
Dennis, 53, and Mr. Mackey, 54 , telling them he had lost confidence
in them. "I expect people to flag the headaches and things I should be
getting involved in. I guess I didn't hammer away enough on these
individuals," he said. Last Thursday, Tenet announced Mr. Mackey's
retirement and said Mr. Dennis had voluntarily left the company. Mr.
Barbakow brought back Trevor Fetter, 42, a trusted lieutenant who had
moved over to a Tenet hospital services affiliate in 2000, and named
him president.
The reshuffle, which was accompanied by a more
full disclosure by Tenet of the role outlier payments played in its
performance, backfired. Tenet shares again fell, leaving its stock
price last Friday at $14.90, down from a high of $52.50 on Oct. 3. Mr.
Barbakow "obviously fumbled the ball to some degree by not asking the
right questions," said David Woodyatt, a buy-side investment analyst
at Harris Bank, a unit of Bank of Montreal. "You get into a situation
where either he knew and didn't tell us, so you can't trust him, or he
didn't know something he should have known."
Write to Rhonda L. Rundle at rhonda.rundle@wsj.com4
and Anna Wilde Mathews at anna.mathews@wsj.com5
|
|
URL for this article:
http://online.wsj.com/article/0,,SB1036780906876999788.djm,00.html
|
|
|
Hyperlinks in this Article:
(1)
http://web.servicebureau.net/conf/meta?i=1112343233&c=2343&m=was&u=/w_ccbn.xsl&date_ticker=11_7_2002_THC
(2) http://wsj.com/health
(3)
http://online.wsj.com/user-cgi-bin/searchUser.pl?action=emailalert
(4) mailto:rhonda.rundle@wsj.com
(5) mailto:anna.mathews@wsj.com
(6)
http://commerce.theplatform.com/MSNBC/November_02/110802/wsj/asx_56/110802_1430_12150.asx
(7) http://online.wsj.com/article/0,,SB1036594448516634068,00.html
(8) http://online.wsj.com/article/0,,SB1036633198491977468,00.html
(9) http://online.wsj.com/article/0,,SB103653660513917308,00.html
(10)
http://online.wsj.com/article/0,,SB1036456831836277708,00.html
|
Updated November 11, 2002 12:30 p.m. EST